The effect of insulin delivery route on lipoproteins in type I diabetic patients on CAPD

Peritoneal Dialysis International

Volumn 19, Issue 2, 1999, Pages 148-153

  Nevalainen, Pasi I ^a,c   Lahtela, Jorma T ^a   Mustonen, Jukka ^a   Taskinen, Marja Riitta ^b   Pasternack, Amos ^a  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

End stage renal disease; HDL cholesterol; Human; Intraperitoneal insulin; Lipoproteins; Type I diabetes; Uremia

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN B; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; ISOPHANE INSULIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NEUTRAL INSULIN; UREA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; UREMIA;

EID: 0033375993     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901900213     Document Type: Article

References (36)

1. Khanna R, Oreopoulos DG. Peritoneal dialysis in diabetic end-stage renal disease. J Diabet Complications 1989; 3:12-17.
2. Stevenson RW, Parsons JA, Alberti KG. Insulin infusion into the portal and peripheral circulation of unanaesthetized dogs. Clin Endocrinol (Oxf) 1978; 8:335-47.
3. De Lemos JA, Hillis DH. Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis. J Am Soc Nephrol 1996; 7:2044-54.
4. Finkelstein FO, Smith JD. Peritoneal dialysis for patients with diabetes and end-stage renal disease. Sorting out the biases? ASAIO J 1996; 42:1-3.
5. Avram MM, Goldwasser P, Burrell DE, Antignani A, Fein PA, Mittman N. The uremic dyslipidemia: a cross-sectional and longitudinal study. Am J Kidney Dis 1992; 20:324-35.
6. Micossi P, Bosi E, Cristallo M, Monti LD, Librenti MC, Petrella G, et al. Chronic continuous intraperitoneal insulin infusion (CIPII) in type I diabetic patients non-satisfactorily responsive to continuous subcutaneous insulin infusion (CSII). Acta Diabetol Lot 1986; 23:155-64.
7. Selam J-L, Kashyap M, Alberti KGMM, Lozano J, Hanna M, Turner D, et al. Comparison of intraperitoneal and subcutaneous insulin administration on lipids, apolipoproteins, fuel metabolites and hormones in type I diabetes mellitus. Metabolism 1989; 38:908-12.
8. Ruotolo G, Micossi P, Galimberti G, Librenti MC, Petrella G, Marcovina S, et al. Effects of intraperitoneal insulin administration on lipoprotein metabolism in type I diabetes. Metabolism 1990; 39:598-604.
9. Ruotolo G, Parlavecchia M, Taskinen M-R, Galimberti G, Zoppo A, Le N-A, et al. Normalisation of lipoprotein composition by intraperitoneal insulin in IDDM: role of increased hepatic lipase activity. Diabetes Care 1994; 17:6-12.
10. Selam J-L, Kashyap ML, Gupta AK, Turner D, Wong ND, Lozano LJ, et al. Alterations in reverse cholesterol transport associated with programmable implantable intraperitoneal insulin delivery. Metabolism 1994; 43:665-9.
11. Dunn FL, Nathan MN, Scavini M, Selam J-L, Wingrove TG, the Implantable Insulin Pump Study Group. Long-term therapy of IDDM with an implantable insulin pump. Diabetes Care 1997; 20:59-63.
12. Lahtela JT, Mustonen J, Pasternack A. Comparison of intraperitoneal and subcutaneous insulin administration on insulin sensitivity and serum lipids in type I diabetic patients on continuous ambulatory peritoneal dialysis treatment. Clin Sci 1995; 88:427-32.
13. 1c results in the FPLC method with Mono S cation exchanger. Clin Chirn Acta 1998; 273:69-79.
14. Havel RJ, Eder HS, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34:1345.
15. Tschöpe W, Koch M, Thomas B, Ritz E, the German Study Group Diabetes and Uremia. Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Nephron 1993; 64:354-8.
16. Selam J-L, Raccah D, Jean-Didier, Lozano JL, Waxman K, Charles, MA. Randomised comparison of metabolic control achieved by intraperitoneal insulin infusion with implantable pumps versus intensive subcutaneous insulin therapy in type I diabetic patients. Diabetes Care 1992; 15:53-8.
17. Bagdade JD, Dunn FL, Eckel RH, Ritter MC. Intraperitoneal insulin therapy corrects abnormalities in cholesteryl ester transfer and lipoprotein lipase activities in insulin-dependent diabetes mellitus. Arterioscler Thromb 1994; 14:1933-9.
18. Miller NE. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987; 113:589-97.
19. Yorioka N, Taniguchi Y, Ito T, Shao JC, Masaki T, Yamashita K, et al. Lipid risk factors for atherosclerotic carotid artery disease in patients on continuous ambulatory peritoneal dialysis. Nephrology 1998; 4:109-12.
20. Kazumi T, Vranic M, Bar-On H, Steiner G. Portal versus peripheral hyperinsulinemia and very low density lipoprotein triglyceride kinetics. Metabolism 1986; 35:1024-8.
21. Schade DS, Eatori RP, Friedman NM, Spencer WJ. Normalisation of plasma insulin profiles with intraperitoneal insulin infusion in diabetic man. Diabetologia 1980; 19:35-9.
22. Sadur CN, Eckel RH. Insulin stimulation of adipose tissue lipoprotein lipase. Use of the euglycemic clamp technique. J Clin Invest 1982; 69:1119-25.
23. Agardh CD, Sartor G, Nilsson-Ehle P. Plasma high density lipoproteins and lipolyic enzyme activities in diabetic patients. Acta Med Scand 1983; 213:123-8.
24. Taskinen M-R. Hyperlipidemia in diabetes. Baillieres Clin Endocrinol Metab 1990; 4:743-75.
25. Lopes-Virella MF, Wohltmann HJ, Loadholt CB, Buse MG. Plasma lipids and lipoproteins in young insulin-dependent diabetic patients: relationship with control. Diabetologia 1981; 21:216-23.
26. Young GA, Kopple JD, Lindholm B, Vonesh EF, De Vecchi A, Scalamogna A, et al. Nutritional assessment of continuous ambulatory peritoneal dialysis patients: an international study. Am J Kidney Dis 1991; 17:462-71.
27. Sreedhara R, Avram MM, Blanco M, Batish R, Avram MM, Mittman N. Prealbumin is the best nutritional predictor of survival in hemodialysis and peritoneal dialysis. Am J idney Dis 1996; 28:937-42.
28. Balaskas EV, Yuan ZY, Gupta A, Meema HE, Blair G, Bargman J, et al. Long-term continuous ambulatory peritoneal dialysis in diabetics. Clin Nephrol 1994; 42:54-62.
29. Nevalainen P, Lahtela JT, Mustonen J, Pasternack A. The influence of peritoneal dialysis and the use of subcutaneous and intraperitoneal insulin on glucose metabolism and serum lipids in type 1 diabetic patients. Nephrol Dial Transplant 1997; 12:145-50.
30. Little J, Phillips L, Russell L, Griffiths A, Russell GI, Davies SJ. Longitudinal lipid profiles on CAPD: their relationship to weight gain, comorbidity, and dialysis factors. J m Soc Nephrol 1998; 9:1931-9.
31. Kagan A, Elimalech E, Lerner Z, Fink A, Bar-Khayim Y. Residual renal function affects lipid profile in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 1997; 17:243-9.
32. Anderson EA, Hiffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilatation in normal humans. J Clin Invest 1991; 87:2246-52.
33. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, et al. Insulin resistance in essential hypertension. N Engl JMed 1987; 317:350-7.
34. Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M. Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels. Kidney Int 1990; 37:980-90.
35. 3 cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction. Circulation 1992; 85:22-9.
36. Schmitz O. Insulin-mediated glucose uptake in nondialyzed and dialyzed uremic insulin-dependent diabetic subjects. Diabetes 1985; 34:1152-9.